undamentalytics Newsletter
Sign in

Roivant Sciences Ltd. income statement

In fiscal 2026, Roivant Sciences Ltd. reported revenue of $8.3m, down 71.6% on the year before, operating income of −$515m (a -6235.7% margin) and net income of −$300m, or −$0.54 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Mar 20212022Mar 20222023Mar 20232024Mar 20242025Mar 20252026Mar 2026LTMJun 2026
Revenue245532332988
Research and development237483454440550682731
Selling, general and administrative—775601687———
General and administrative260———591610642
Operating income−1,071−1,352−9074,497−1,003−515−596
Interest expense372835———
Income before tax−899−924−8854,568−682−265−290
Income tax2042248133125
Net income−809−845−1,0094,349−172−300−266
Diluted EPS−$1.28−$1.26−$1.42$5.23−$0.24−$0.54−$0.38
Diluted shares (average)630m670m713m831m725m694m704m
EBITDA—−1,346−8884,519−989−512−593

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: EVAX vs ROIVADAG vs ROIVROIV vs TCRX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Roivant Sciences Ltd.'s SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Roivant Sciences Ltd.